Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
grade C 2.26 7.11% 0.15
CRIS closed up 7.11 percent on Thursday, September 19, 2019, on 84 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CRIS trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 50 DMA Bullish 7.11%
180 Bullish Setup Bullish Swing Setup 7.11%
Overbought Stochastic Strength 7.11%
Fell Below 50 DMA Bearish 8.13%

Older signals for CRIS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Cancer Drugs Surgery Solid Tumors Drug Discovery Breast Cancer Multiple Myeloma Cancer Therapeutics Hematological Cancers Protein Kinase Inhibitors Phosphoinositide 3 Kinase Inhibitor Advanced Non Small Cell Lung Cancer Refractory Solid Tumors
Is CRIS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.9
52 Week Low 0.6
Average Volume 207,192
200-Day Moving Average 1.5814
50-Day Moving Average 2.1118
20-Day Moving Average 1.9875
10-Day Moving Average 2.032
Average True Range 0.1279
ADX 14.58
+DI 25.2763
-DI 14.0728
Chandelier Exit (Long, 3 ATRs ) 1.8763
Chandelier Exit (Short, 3 ATRs ) 2.2037
Upper Bollinger Band 2.1996
Lower Bollinger Band 1.7754
Percent B (%b) 1.14
BandWidth 21.343396
MACD Line 0.0314
MACD Signal Line -0.0057
MACD Histogram 0.0371
Fundamentals Value
Market Cap 325.16 Million
Num Shares 144 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -4.52
Price-to-Sales 27.52
Price-to-Book 24.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.51
Resistance 3 (R3) 2.48 2.37 2.47
Resistance 2 (R2) 2.37 2.31 2.38 2.45
Resistance 1 (R1) 2.32 2.27 2.34 2.34 2.44
Pivot Point 2.21 2.21 2.22 2.22 2.21
Support 1 (S1) 2.15 2.14 2.18 2.18 2.08
Support 2 (S2) 2.04 2.10 2.05 2.07
Support 3 (S3) 1.99 2.04 2.05
Support 4 (S4) 2.01